ClinicalTrials.Veeva

Menu
F

Florida Retina Institute | North Florida - Jacksonville Southside

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KUS121
Aflibercept
ONL1204
BI 771716
BI 764524

Parent organization

This site is a part of Florida Retina Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 7 total trials

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (ELARA)

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Enrolling
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based th...

Enrolling
Central Retinal Artery Occlusion
Drug: KUS121 high dose
Drug: Sham procedure
Locations recently updated

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling
Diabetic Retinopathy
Drug: BI 764524
Drug: Aflibercept (Eylea®) - US only

Trial sponsors

Boehringer Ingelheim logo
Bayer logo
K
Novartis logo
O
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems